

## STEROID HORMONE REGULATION OF ANGIOGENESIS IN THE PRIMATE ENDOMETRIUM

Eugene D. Albrecht<sup>1</sup> and Gerald J. Pepe<sup>2</sup>

<sup>1</sup> Department of Obstetrics, Gynecology and Reproductive Sciences, The Center for Studies in Reproduction, The University of Maryland School of Medicine, Baltimore, Maryland 21201 and the <sup>2</sup> Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia 23501

### TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Vascularization of the Primate Endometrium
4. Angiogenesis
  - 4.1. Vascular Endothelial Growth Factor (VEGF)
  - 4.2. Angiopoietin-1 and -2
  - 4.3. Basic Fibroblast Growth Factor (bFGF)
  - 4.4. Other Angiostimulatory and Angioinhibitory Factors
5. Expression of Angiogenic Factors in the Endometrium During the Menstrual Cycle
6. Steroid Hormone Regulation of VEGF Expression and Vascularization in the Endometrium
  - 6.1. Estrogen and Progesterone Receptors
  - 6.2. Estrogen and Progesterone Action
    - 6.2.1. Estrogen
    - 6.2.2. Progesterone
    - 6.2.3. Correlation of Steroid Hormones, VEGF Expression and Angiogenesis During Menstrual Cycle
  - 6.3. Direct Actions of Estrogen on Vascular Cells
  - 6.4. Other Regulatory Elements
7. Perspective
8. Acknowledgment
9. References

### 1. ABSTRACT

The human endometrium develops new capillaries from existing microvessels, i.e. angiogenesis, which then undergo maturation and remodeling, i.e. investment of microvessels with periendothelial mural cells, into a new vascular network during each menstrual cycle. Improper vascularization of the endometrium may cause implantation failure and infertility. Estrogen and progesterone have pivotal roles in establishing this vascular bed, but the cellular sites and mechanisms of action of these steroid hormones are incompletely understood. Vascular endothelial growth factor (VEGF), angiopoietin-1, and angiopoietin-2 and their receptors are expressed in the human and nonhuman primate endometrium and interact to control vascular development and remodeling. VEGF synthesis within and neovascularization of the endometrium seem to be sustained and ongoing processes designed to progressively promote growth and development of the endometrium with advancing stages of the menstrual cycle. However, estrogen rapidly upregulates VEGF expression by endometrial glandular epithelial and stromal cells *in vivo* in the nonhuman primate and *in vitro* in the human. Reports of the effects of progesterone on endometrial VEGF formation, however, are inconsistent and may reflect regulatory actions on particular isoforms of VEGF. In addition, estrogen has effects on vascular

endothelial and smooth muscle cells, which may be direct or mediated by VEGF. Very little is known, however, about the steroid hormone regulation of other angiostimulatory and angioinhibitory factors, e.g. angiopoietin-1 and -2, in the endometrium. Moreover, the role of steroid hormones acting directly, or indirectly via VEGF and other angiogenic factors, on expression of integrins, cell adhesion and other molecules required for cell-cell and cell-extracellular matrix interactions important for angiogenesis in the human and nonhuman primate endometrium is largely unknown. Finally, further study is needed of cell-specific responsiveness and function in the human endometrium with respect to steroid hormone regulation of angiogenesis.

### 2. INTRODUCTION

The endometrium undergoes extensive development of new capillaries from existing microvessels, i.e. angiogenesis, as well as vascular maturation and remodeling during each menstrual cycle (1-3). The newly developed vascular system in turn supplies nutrients and oxygen to support the growth and cellular differentiation of the endometrium for blastocyst implantation. Abnormal vessel development may cause implantation failure and

## Angiogenesis in the Primate Endometrium

lead to dysfunctional bleeding, endometriosis, and menorrhagia, major health problems and causes of infertility in women. Vascular growth in the endometrium during each menstrual cycle is highly unique, because angiogenesis is typically a rare event in the adult, normally occurring only during fetal development and wound healing.

Although the steroid hormones, estrogen and progesterone, have pivotal roles in establishing the endometrial vascular bed during each menstrual cycle (4), the cellular sites and mechanisms of action of these hormones are incompletely understood. Vascular endothelial growth factor (VEGF) and other angiostimulatory, e.g. angiopoietin-1, and angioinhibitory, e.g. angiopoietin-2 and thrombospondin-1, factors interact in a coordinated manner to control development, maturation, and remodeling of blood vessels (5-7).

In this review, experimental evidence will be presented that estrogen and progesterone regulate VEGF expression in the endometrium and the concept developed that via the regulation of expression of VEGF, and possibly other angiostimulatory factors, these steroid hormones promote angiogenesis and consequently growth and development of the endometrium during the human and nonhuman primate menstrual cycle.

### 3. VASCULARIZATION OF THE PRIMATE ENDOMETRIUM

Changes in vascularization of the endometrium during the menstrual cycle were first described by Markee (8), in autologous transplants of rhesus monkey endometrium in the anterior chamber of the eye. During the menstrual cycle, endometrial angiogenesis occurs at the time of menstruation for repair of the vascular bed in the basalis zone, during the proliferative phase when spiral arteries lengthen and branch and there is rapid growth of the functionalis zone, and during the secretory phase when spiral arteries exhibit growth and coiling within the functionalis layer. Thus, upon initiation of a new menstrual cycle, preexisting vessels in the zona basalis give rise via angiogenesis to capillary sprouts. These sprouts become encapsulated with smooth muscle cells and elastic tissues, converting them into arterioles and arteries, which project almost to the luminal epithelium where they branch to form a rich subepithelial capillary plexus. With advancing stages of the menstrual cycle, these newly formed spiral arteries progressively lengthen, branch, and coil as arterial growth exceeds endometrial thickening (9). In the absence of implantation and demise of the corpus luteum, the spiral arteries close to the myometrial-endometrial junction exhibit vasoconstriction, resulting in necrosis and sloughing of most of the zona functionalis at the end of the cycle. In contrast, the basal arteries that ramify in the deepest layer of the endometrium do not undergo vasoconstriction and consequently remain intact to preserve the zona basalis as a bed for reconstruction after menstruation. The periodic proliferation and shedding of the endometrium during each menstrual cycle exemplifies a dynamic process of programmed angiogenesis.

## 4. ANGIOGENESIS

Angiogenesis proceeds in at least two phases: (1) the activation phase, in which endothelial cells degrade their basement membrane via proteolytic enzymes, e.g. matrix metalloproteinases (MMPs) and enzymes of the plasminogen activator system, and undergo proliferation and migration in the surrounding stroma to form capillary sprouts; and (2) the resolution phase, in which proliferation and migration cease, a new basement membrane is deposited, and cells organize and mature into a new vessel. Both phases appear to be determined by a balance between stimulatory and inhibitory regulatory factors. Considering the complexity of vascular remodeling of the primate endometrium during the course of the menstrual cycle, it is likely that several growth factors are involved in this process. Although several pleiotropic growth factors described below are angiostimulatory, VEGF is the most prominent and well characterized angiogenic factor.

### 4.1. VEGF

VEGF is the prototype of a family of potent endothelial-specific mitogens which stimulates vascular endothelial cell proliferation, migration, organization into tubules and permeability (reviewed in 5, 10-12). Although other factors, e.g. epidermal growth factor, transforming growth factor, and platelet-derived growth factor, can also induce neovascular responses these agents are not specific for vascular endothelial cells. Alternative exon splicing of a single VEGF gene results in the synthesis of at least 5 polypeptide isoforms of 121, 145, 165, 189, and 206 amino acids (13). The active forms of these VEGF glycoproteins are homodimers linked via disulfide bridges (14, 15), and the various isoforms may be further processed by post-translational mechanisms, e.g. by plasmin. The existence of multiple VEGF species implies that they have different biological properties, distribution, and synthesis. The most widely expressed forms, VEGF 121 and VEGF 165, are freely soluble, while the 189 and 206 species are sequestered and thus remain in the extracellular matrix (5, 16). An important biological property that distinguishes the different VEGF isoforms, therefore, is their ability to bind to extracellular matrix components, such as heparin and heparan-sulfate. Thus, VEGF 121 lacks the amino acids encoded by exons 6 and 7 of the gene and binds weakly, if at all, to heparin (17). The 121 and 165 amino acid isoforms promote permeabilization of blood vessels and proliferation of vascular endothelial cells (18), while VEGF 189 uniquely induces endothelial cell proliferation (16).

Two structurally related vascular endothelial cell-specific tyrosine kinase receptors, fms-like tyrosine kinase (flt-1) and kinase domain region (KDR/flk-1), bind VEGF with high affinity (19). KDR/flk-1 appears essential for endothelial cell differentiation, while flt-1 may be involved in vascular assembly (20, 21). The physiological importance of the VEGF flt-1/KDR/flk-1 receptor system in blood vessel formation is based on several classical studies showing that: (1) the spatiotemporal expression of VEGF and its receptors correlates closely with angiogenesis in various systems (5); (2) antibodies to VEGF

## Angiogenesis in the Primate Endometrium

or flk-1 (22-24) or administration of truncated soluble flt-1 receptor to rats (25) or marmoset monkeys (26) block angiogenesis; (3) targeted inactivation of the VEGF gene in mice resulted in disruption of vasculogenesis and induced embryonic lethality (27, 28); and (4) mice lacking flt-1 or KDR/flk-1 die in early development because of the absence of vasculogenesis (20, 21).

### 4.2. Angiopoietin-1 and -2

Two other more recently discovered 75 kDal secreted proteins, angiopoietin-1 and angiopoietin-2, appear to work in concert with VEGF in signaling vascular morphogenesis by binding to the endothelial cell-specific transmembrane tyrosine kinase receptor Tie-2. The phase-specific expression of angiopoietin-1 and -2 and the results of Tie-2 gene knock-out studies (29, 30) have led to the proposal (6, 7) that VEGF, angiopoietin-1 and -2 interact to control angiogenesis, and vessel remodeling, maturation, and regression. Thus, it has been proposed that early in the process of vasculogenesis VEGF binds to the KDR flk-1 receptor to stimulate endothelial cell migration and proliferation, and simultaneously binds to the flt-1 receptor to promote endothelial cell-cell interactions and capillary tube formation. Angiopoietin-1 then binds to the Tie-2 receptor to recruit and stimulate the association of peri-endothelial support cells, e.g. pericytes and smooth muscle cells, with endothelial cells to mature and stabilize the newly-formed blood vessels and also promote endothelial cell survival. Angiopoietin-2, by exerting an antagonistic action on the angiopoietin-1/Tie-2 receptor signal, causes the vessel wall to loosen, reducing endothelial cell contacts with matrix and disassociating peri-endothelial support cells, rendering the endothelial cells more accessible and responsive to VEGF, presumably to further promote angiogenesis. However, in the relative absence of VEGF, angiopoietin-2 by loosening the endothelial cell-matrix interaction apparently elicits endothelial cell death via apoptosis. This sequential cascade of VEGF, angiopoietin-1 and -2 events may be the blueprint for the development, remodeling and regression of a new vascular system within the endometrium during each menstrual cycle.

The subcellular signaling mechanisms and pathways underlying VEGF and angiopoietin action are incompletely understood. However, it appears that adapter proteins Grb, protein tyrosine phosphatase SHP2, and STAT, which have been implicated in cell survival, migration, proliferation and differentiation (31), may modulate angiopoietin-Tie receptor activation. Moreover, endothelial cell-cell and endothelial cell-extracellular matrix interactions are intricately involved in cell proliferation, survival, migration and remodeling processes essential for vascularization of the endometrium. VEGF and angiopoietin-1/-2 seem to modulate the latter processes by controlling expression of integrins, extracellular matrix proteins and cell adhesion molecules (reviewed in 32). For example, VEGF induces expression of  $\alpha v\beta 3$ ,  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  integrins which function as vascular cell adhesion molecules and as receptors for interstitial collagen in microvascular endothelial cells (33).

### 4.3. Basic Fibroblast Growth Factor (bFGF)

Other than VEGF, bFGF is the most widely recognized growth factor thought to be important to

angiogenesis. bFGF, a member of the FGF superfamily, is comprised of nine distinct gene products (reviewed in 34, 35), is a cationic 18 kDal polypeptide which lacks a signal peptide and therefore fails to enter the classical secretory pathway, and induces angiogenesis *in vivo* and in three-dimensional invasion models *in vitro* (36-38). However, unlike VEGF, the stimulatory effects of bFGF are not restricted to endothelial cells, but also involve proliferation, migration, and differentiation of smooth muscle cells and fibroblasts, all of which express FGF receptors (39). For example, suppression of bFGF expression by adenovirus transfer of an antisense bFGF to cultured vascular smooth muscle cells decreased proliferation of and induced apoptosis in these cells (40). Although the level of angiogenesis in microvascular endothelial cell monolayers was five-fold greater in the presence of bFGF and VEGF than with either one alone, suggesting that these factors act synergistically (38, 41), VEGF was much more effective than bFGF in stimulating endometrial microvascular endothelial cell proliferation (42). Recently, KDR/flk-1 tyrosine kinase aminophthalazine antagonists were shown to inhibit bFGF as well as VEGF-induced angiogenesis *in vitro*. However, because endogenous VEGF was required for this effect, it appears that these antagonists act on bFGF by interrupting an autocrine bFGF-VEGF loop (43).

The bFGF-induced endothelial responses are mediated via a high affinity type 1-C receptor (44), however, three other transmembrane tyrosine kinase receptors and a large number of FGF receptor variants generated by alternative mRNA splicing and differential polyadenylation also exist. This diversity in receptor expression results in a complex and incompletely understood pattern of overlapping binding specificities and actions for the various FGF's.

### 4.4. Other Angiostimulatory and Angioinhibitory Factors

Four closely related genes which show homology with VEGF, i.e. VEGF-B, VEGF-C, VEGF-D, and placenta growth factor, also may be involved in blood vessel development, although the roles for these factors are poorly understood. VEGF-C and -D bind to KDR/flk-1 and flt-4 receptors, while the receptor for VEGF-B is unknown. VEGF-C induces angiogenesis *in vivo* (45). Placenta growth factor forms heterodimers with VEGF and binds to flt-1, however, it is very weakly mitogenic when compared to VEGF (46). Angiogenin, a heparin-binding 14.1-kDal single-chain polypeptide and member of the pancreatic ribonuclease superfamily, also is a potent inducer of angiogenesis (47). Other factors, e.g. epidermal growth factor (48), platelet-derived growth factor (49) and transforming growth factor  $\alpha$  and  $\beta$  (50), also promote certain aspects of angiogenesis.

Angiogenesis and vascular remodeling (i.e. investment of microvessels with periendothelial support cells such as vascular smooth muscle cells and pericytes) are orchestrated by coordinated interactions of stimulatory and inhibitory factors. One of the most widely studied angioinhibitory molecules is thrombospondin-1, a 450-kDal glycoprotein released from platelet granules by thrombin,

## Angiogenesis in the Primate Endometrium

which is deposited in and interacts with extracellular matrix and cell surface integrins (51, 52). Thrombospondin-1 exerts antagonistic effects on vascular endothelial cell proliferation, migration, and assembly into microvessels and induces vascular endothelial cell apoptosis (53). Thrombospondin-1 is expressed in human endometrial stromal cells and is increased by progesterone (52).

### 5. EXPRESSION OF ANGIOGENIC FACTORS IN THE ENDOMETRIUM DURING THE MENSTRUAL CYCLE

In the human, VEGF and angiopoietin-1 and -2 mRNA and protein have been localized by *in situ* hybridization and immunocytochemistry in glandular epithelium and stroma (54-57). Each of the VEGF isoforms is expressed in the human endometrium, although the 121 and 165 species seem to be the most important physiologically (54). Endometrial microvascular endothelial cells also express the flt-1 and KDR/flk-1 receptors (58-60) and pericytes/smooth muscle precursor cells express the Tie-2 receptor (7). Levels of VEGF mRNA and protein in whole endometrium (55, 56) and glandular epithelium (61, 62), and VEGF formation by endometrial cells in culture (62), appeared somewhat greater in the secretory than early proliferative stages of the human menstrual cycle, although VEGF mRNA expression appeared to decrease in the stroma during the secretory phase (54). Others have reported that VEGF immunostaining of endometrial glandular and stromal cells (60, 63, 64), VEGF protein formation by explants of glandular epithelial and stromal cells (65) and endometrial flt-1 and KDR/flk-1 receptor expression (58) did not change during the course of the human menstrual cycle, despite the surges in estrogen and progesterone levels.

Steady-state VEGF mRNA levels in glandular epithelial and stromal cells, isolated from the baboon endometrium by laser capture microdissection, also were relatively similar in the proliferative, midcycle estradiol surge and secretory phases of the menstrual cycle (66), although the levels of VEGF mRNA and protein within the stromal compartment appeared to decline somewhat in the secretory phase. Thus, VEGF expression by glandular epithelial and stromal cells, and flt-1 and KDR/flk-1 receptor expression within the respective vascular endothelium are available throughout the menstrual cycle as components of the angiogenic system to promote vascular reconstruction of and angiogenesis within the endometrium. Indeed vessel density and percent vascularized area of the baboon (66) and human (60, 67, 68) endometrium, and endothelial cell mitosis in the human endometrium (65, 69), remain relatively constant throughout the menstrual cycle. Therefore, VEGF synthesis within and neovascularization of the endometrium seem to be sustained and ongoing processes designed to progressively promote growth and development of the endometrium with advancing stages of the menstrual cycle.

Because 80% of glandular epithelial VEGF is thought to be secreted from the luminal surface (70), it has been suggested (65) that most of the VEGF produced in the

glands does not have a role in endometrial angiogenesis. It is possible, therefore, that VEGF synthesized locally within the stroma and/or vascular endothelial cells (63), pericytes (71, 72), and/or vascular smooth muscle cells (73) has the more important role in regulating, in a paracrine/autocrine manner, vasculogenesis within the endometrium. Moreover, since neutrophils constitutively express VEGF focally in association with microvessel endothelial cells (74), it has been proposed that cells within the vasculature are the principal source of angiogenic factors for non-sprouting angiogenesis, i.e. intussusception and elongation, within the endometrium.

bFGF and EGF, and their respective receptors, are also expressed in glandular and luminal epithelial cells, basal lamina of blood vessels, stroma, and extracellular matrix of the human endometrium (60, 75-77). Although endometrial stromal cell bFGF and FGF receptor expression was higher during the proliferative phase of the menstrual cycle (77), others reported that bFGF expression did not change during the menstrual cycle (60, 75). Because FGF receptor was markedly reduced in women with menorrhagia, Sangha *et al* (77) have suggested that FGF is critical for endometrial regeneration. In contrast, because bFGF was increased in atrophic endometrium of postmenopausal women (75), and FGF type-1 and -2 receptors were only sparsely expressed in human endometrial blood vessels, it has been suggested that bFGF may be of lesser importance in regulating angiogenesis in the uterus (60).

Finally, angiogenin mRNA and protein are expressed by endometrial glandular epithelial and stromal cells and increase during the mid to late secretory phase of the human menstrual cycle (78). Since vascular smooth muscle cells around uterine spiral arteries show increased proliferative activity during this interval (79), and angiogenin stimulates proliferation of vascular smooth muscle cells and endothelial cells (80), Koga *et al.*, (78) have suggested that angiogenin may participate in the process of thickening and convolution of the arterioles during the secretory phase of the menstrual cycle.

### 6. STEROID HORMONE REGULATION OF VEGF EXPRESSION AND VASCULARIZATION IN THE ENDOMETRIUM

#### 6.1. Estrogen and Progesterone Receptors

The receptors for both estrogen  $\alpha$  and  $\beta$  and progesterone are present within the nuclei of glandular epithelial and stromal cells of the human (81-84) and nonhuman primate (84, 85) endometrium during the menstrual cycle. In elegant studies, estradiol was shown to increase estrogen and progesterone receptor mRNA and protein expression in glandular epithelial, stromal and vascular smooth muscle cells in ovariectomized rhesus monkeys (4, 85-87). As estrogen was withdrawn and progesterone elevated to mimic the peripheral serum levels characteristic of midsecretory phase, estrogen (4, 85, 87, 88) and progesterone (4, 82, 85, 88) receptors were markedly suppressed in glandular epithelial and stromal cells of the functionalis zones I-III, but not basalis zone IV, or in vascular smooth muscle or perivascular stromal cells of the spiral arteries. These results are consistent with observations in the

## Angiogenesis in the Primate Endometrium

human, where immunocytochemical staining for progesterone receptor protein was significantly reduced during the mid and late secretory phase compared to the proliferative phase of the menstrual cycle (61, 84, 89). It is apparent, therefore, that estrogen generates the receptors for estrogen and progesterone during the proliferative phase, and that the surge in progesterone during the secretory phase is responsible for the decline in receptor expression. Thus, the receptors for both estrogen and progesterone are expressed in a cell and zone-specific manner to mediate the action of these hormones on cell proliferation, differentiation (90) and angiogenesis within the human and nonhuman primate endometrium.

### 6.2. Estrogen and Progesterone Action

#### 6.2.1. Estrogen

It has been generally concluded that estrogen has a pivotal role in establishing the new vascular bed and promoting growth and cellular differentiation within the endometrium during each menstrual cycle (1, 2, 4, 91). The uterotrophic effects of estrogen are both early and long-term. The early events, e.g. increased vascular permeability (92, 93), create an environment optimal for cellular hypertrophy and hyperplasia and consequently angiogenesis. Thus, in the rat a single injection of estradiol enhanced vascular permeability and water inhibition within 3-6 h (94-96) and endothelial cell mitosis indicative of basal sprouting of capillaries within 24 hours (97).

There is compelling evidence in various species to support the concept that the tropic effects of estrogen on vascularization of the uterus are mediated by VEGF. Thus, estradiol rapidly elevated VEGF mRNA levels and vascular endothelial cell proliferation *in vivo* in the mouse and rat (97-101) and sheep (102-103) uterus. The estrogen induction of VEGF in the rat uterus occurred primarily in the stroma (104), involved upregulation of the 120 and 164 VEGF rodent species (100), and was blocked by estrogen receptor antagonist ICI 182,780 (105) suggesting regulation via the classical estrogen receptor pathway. Consistent with this concept, estrogen had no effect on angiogenesis in transgenic mice with targeted disruption of the estrogen receptor gene (106).

Although it is difficult to study the potential effect of ovarian steroid hormones on endometrial angiogenesis *in vivo* in the human, in cultures of isolated human endometrial epithelial and stromal cells, estrogen rapidly upregulated VEGF mRNA levels and protein (54, 56, 107, 108), an effect blocked by ICI 182,780 (109). Estradiol also stimulated DNA synthesis within and proliferation of human endometrial vascular endothelial cells *in vitro* (110).

In the baboon, used as a nonhuman primate model to study human reproductive endocrinology (111), VEGF mRNA levels in glandular epithelial and stromal cells isolated by laser capture microdissection and VEGF immunoreactivity in the endometrium were decreased to very low values by ovariectomy which suppressed serum estrogen and progesterone to nondetectable levels (66). Chronic administration of estradiol to ovariectomized baboons via silastic implants in levels which replicated the hormonal pattern of the proliferative phase of the menstrual cycle,

returned endometrial glandular epithelial and stromal cell VEGF mRNA and protein expression to normal (112). The estrogen-dependent stimulation of endometrial VEGF expression observed in ovariectomized baboons is similar to that shown in the rhesus monkey by Nayak and Brenner (113). Acute administration of estradiol to ovariectomized baboons significantly increased glandular epithelial and stromal VEGF mRNA levels within 2 hours and the width of paracellular clefts between adjacent endometrial microvascular endothelial cells, indicative of increased microvascular permeability, within 6 hours (114). Therefore, it appears that ovarian estrogen has a major role in regulating and maintaining VEGF synthesis within the glandular epithelial and stromal cells during the primate menstrual cycle. Moreover, the rapid estrogen-induced up regulation of endometrial VEGF expression precedes, and therefore may mediate, the early action of estrogen on microvascular permeability, an early event in angiogenesis (92, 93).

In addition to effects on VEGF, estrogen also stimulated bFGF synthesis in human endometrial adenocarcinoma HEC-1 cells (115), however, there are conflicting reports on the effects of and mechanisms underlying the steroid hormone regulation of this growth factor (116).

Although sequences corresponding to classical estrogen response elements have not been identified in the 5'-flanking region of the VEGF gene, consensus half-palindromic sequences which bound estrogen receptor alpha in band shift assays and which confer estrogen inducibility to reporter constructs have been identified in two regions of the gene, one in the 5'-untranslated region (117). In primary human endometrial epithelial and stromal cells, as well as Ishikawa endometrial adenocarcinoma cells, estradiol stimulated VEGF gene transcription through a functional single variant estrogen response element located 1.5-kb upstream from the transcriptional start site (107). Considering these observations, plus findings that VEGF induction in the uterus by estrogen is rapid, blocked by antiestrogens and inhibited by actinomycin D but not puromycin or cycloheximide (100, 101), it is likely that the regulatory effects of estrogen on VEGF expression in the uterus are mediated by the estrogen receptor.

#### 6.2.2. Progesterone

Progesterone also regulates endometrial angiogenesis and VEGF expression, however, there is considerable inconsistency in the literature on its specific role. For example, in nonhuman primates, the progesterone antagonist ZK137316 inhibited spiral artery development and endometrial proliferation (118), suggesting a stimulatory role for progesterone in these events. Moreover, Norplant which contains the synthetic progestin levonorgestrel increased endometrial microvascular endothelial cell density in women (67, 119). Therefore, it has been suggested that the significant growth of the coiled arteriolar system in the endometrium during the secretory phase of the menstrual cycle may reflect the influence of luteal progesterone (120). These effects of progesterone on endometrial vascular development may be mediated by VEGF, because chronic administration of progesterone to cynomolgus monkeys in which ovarian

## Angiogenesis in the Primate Endometrium

function was suppressed by GnRH administration, increased VEGF immunorexpression in the endometrial stroma (121). Progesterone also induced endometrial VEGF expression *in vivo* in the rat (98, 101), and *in vitro* in the human (56), however, the magnitude of increase was less and the onset of induction slower than observed by estrogen.

In contrast to the stimulatory effects shown for progesterone on endometrial angiogenesis, a negative correlation has been reported between progesterone receptor and VEGF expression in endometrial glandular epithelium during the normal human menstrual cycle, results consistent with the notion that progesterone suppresses VEGF expression (61). Indeed, administration of oral contraceptives, containing a progestin in combination with ethinyl estradiol, to normal women decreased glandular epithelial VEGF immunostaining (61). Moreover, progesterone inhibited VEGF secretion by human decidualized stromal cells (122) and endometrial angiogenesis (10) when examined by *in vitro* assay systems. Consistent with the latter findings, acute simultaneous administration of estradiol and progesterone to ovariectomized baboons diminished the stimulatory effect of estrogen alone on endometrial glandular epithelial and stromal cell VEGF mRNA and protein expression (114). Several studies have shown that endometrial arteriole development is decreased by long-term progestin administration (123, 124). Moreover, there is substantial evidence that chronic use of progestin-containing oral contraceptive pills leads to abnormalities in endometrial microvessel structure (125), via a reduction in basal lamina collagen, laminin, and heparan sulfate proteoglycan. The latter changes may contribute to vascular fragility, dilation of superficial vessels (126), a reduction in vascular perfusion, and a decrease in endometrial vascular density (124), and consequently breakthrough bleeding. Brenner and colleagues (127) have shown both in the human and macaque that the KDR/flk-1 receptor, normally only expressed in the vascular endothelium, was markedly upregulated in stromal cells of the superficial endometrial zones upon progesterone withdrawal during the premenstrual phase. The increase in receptor expression was cell and zone specific and because promatrix metalloproteinase (MMP-1) was coordinately upregulated in the same stromal cells, it was suggested that VEGF-KDR/flk-1 interaction may influence MMP expression and thus play a role in the induction of menstruation (127).

Therefore, apparently conflicting studies exist on whether progesterone stimulates, inhibits or has no effect on VEGF expression and angiogenesis in the endometrium. Although the VEGF gene does not contain a classical progesterone response element, the 5'-flanking region contains sequences that confer progestin inducibility to reporter constructs in transfection studies (101). Some of the apparently disparate results reported for progesterone may reflect the need to consider particular VEGF isoforms. For example, considerable expression of VEGF 189 occurs in the human endometrium during the mid-late secretory phase, and estradiol plus progesterone stimulated VEGF 189 expression upon the differentiation of isolated human endometrial stromal into decidual cells (128). Moreover, the effect of progesterone may be cell-specific, because progesterone

increased VEGF secretion by human endometrial epithelial cells but decreased expression by endometrial stromal fibroblasts (122).

Thus, regulation of uterine VEGF and angiogenesis very likely results from an interplay of estrogen and progesterone, however, the specific role(s) and site(s) of action of progesterone remain unclear.

### 6.2.3. Correlation of Steroid Hormones, VEGF Expression and Angiogenesis During the Menstrual Cycle


Despite the cyclical surges in estrogen and progesterone, human endometrial microvascular density (60, 67) and vascular endothelial cell proliferation (65, 129) and density (61), as well as VEGF expression, remain relatively constant throughout the menstrual cycle. Consequently, some investigators (61, 65, 130) have concluded that there is no relationship between, and/or steroid hormones are not the main regulators of, these processes in the human endometrium.

The limitation of studying endometrial angiogenesis during the normal human menstrual cycle, and difficulty in conducting invasive *in vivo* studies in humans, have led to apparently conflicting information on the effect of estrogen and progesterone on endometrial VEGF expression and vascularization. However, although endometrial VEGF mRNA levels and vessel density also remain relatively constant during the baboon (66) and rhesus monkey (113) menstrual cycle, there was a striking decline in endometrial VEGF expression and size after ovariectomy, effects which were completely reversed by estradiol or estradiol and progesterone (66, 113). It appears, therefore, that endometrial VEGF synthesis is dependent upon estrogen and that the levels of estrogen preceding and following the midcycle surge, albeit low, are nevertheless sufficient to bind to estrogen receptor to maintain VEGF synthesis and thus promote endometrial angiogenesis throughout the course of the advancing menstrual cycle.

### 6.3. Direct Actions of Estrogen on Vascular Cells

Although estrogen and progesterone may promote endometrial angiogenesis by upregulating the expression of angiogenic factors such as VEGF by glandular epithelial and stromal cells during the menstrual cycle, these steroid hormones may also exert direct actions upon vascular endothelial and smooth muscle cells. Thus, estrogen and progesterone receptors have been detected in vascular smooth muscle cells (84, 131) and vascular endothelial cells (132, 133) within the endometrium, although others have not found estrogen receptors in endothelial cells (134, 135). In cell culture, estrogen promoted vascular endothelial cell proliferation (136), migration (137), and survival (138). The stimulatory effect of estradiol on myometrial microvascular endothelial cell proliferation may reflect an estrogen-dependent increase in expression of the KDR/flk-1 receptor on these cells (139). In ovariectomized mice, estrogen stimulated endometrial vascular endothelial cell proliferation within 24 hours and glandular epithelial cell proliferation after 48 hours (140), raising the possibility that endometrial tissue growth and mass are regulated by growth of endothelial cells (141). Although the effects of estrogen on microvessel cell function may be direct, it is also possible they are modulated

## Angiogenesis in the Primate Endometrium



**Figure 1.** Proposed role of ovarian estrogen on endometrial glandular epithelial (GE) and stromal (S) VEGF expression, angiogenesis, and growth in the primate.

in an autocrine and/or paracrine manner via VEGF. Thus, estrogen stimulated VEGF expression by vascular smooth muscle cells (5, 131, 142), and anti-VEGF antibody blocked the increase in vascular endothelial cell proliferation elicited by estradiol (143).

### 6.4. Other Regulatory Elements

Factors in addition to estrogen and progesterone, notably hypoxia, cytokines, and thrombin are extremely potent in their capacity to upregulate VEGF expression in various tissues including the human endometrium (5, 62, 144, 145). Hypoxia also upregulates (146) and TGF $\beta$  down regulates (147) expression of the VEGF flk-1 receptor in vascular endothelial cells. However, the physiological role of hypoxia upon endometrial VEGF expression may be most important at the time of menstruation when both oxygen tension and steroid hormone levels become very low (130). Indeed, shortly preceding menstruation there is a striking increase in expression of VEGF mRNA in the baboon (Albrecht ED, Pepe GJ, unpublished observations) and VEGF and KDR/flk-1 receptor in the human and rhesus monkey endometrium (113, 127). Under these circumstances, hypoxia and/or other factors such as cytokines important to wound healing may overcome the absence of other regulatory factors, e.g. estrogen, resulting in the induction of VEGF synthesis, which may be important for vessel repair and reconstruction.

## 7. PERSPECTIVE

A complex interplay of different cell types which express angiostimulatory agents such as VEGF, angiopoietin-1, and bFGF, and angioinhibitory factors such as thrombospondin-1, and which respond in a coordinated manner to regulatory factors such as estrogen and progesterone, exist to promote and maintain a balance in

the level of vessel growth within the human endometrium during each menstrual cycle. The physiological roles and sites of action of VEGF and angiopoietin -1 and -2 in vascular development have primarily been elucidated by transgenic approaches in mice, while the majority of the studies of the regulatory effects of estrogen and progesterone on the expression of angiogenic factors in the endometrium have been conducted *in vivo* in laboratory rodents and *in vitro* with human cells. However, because of the difficulty for ethical reasons in conducting invasive *in vivo* experimental studies in the human, investigation of the regulatory actions of VEGF/PF, angiopoietin-1, and angiopoietin-2 and consequently vessel development and remodeling in the human endometrium has been limited. Thus, many of the *in vivo* studies on angiogenesis in the human have been conducted during the normal menstrual cycle where relatively little change in endometrial VEGF expression and microvessel density were observed despite the cyclical surges in estrogen and progesterone. Consequently, these observations have led to the conclusion that steroid hormones do not have a role in regulating VEGF or angiogenesis in the endometrium. However, studies conducted *in vivo* in nonhuman primates, in which the hormonal milieu can be experimentally manipulated, show that endometrial glandular epithelial and stromal VEGF expression was decreased to baseline levels by ovariectomy and restored to normal by chronic administration of estrogen in levels which replicated those observed during the normal menstrual cycle (Figure 1). Therefore, the relatively low levels of estrogen to which the uterus is exposed preceding and following the midcycle surge in estrogen apparently are sufficient to sustain VEGF expression throughout the menstrual cycle and only when estrogen is decreased to nondetectable values, e.g. after ovariectomy, does VEGF formation substantially decline. Thus, VEGF and its receptors are expressed and available as components of the angiogenic system throughout the menstrual cycle to promote vascular reconstruction of the endometrium. Collectively, the studies conducted *in vivo* in the laboratory rodent, *in vitro* with isolated human endometrial cells, and *in vivo* in nonhuman primates are consistent with the proposal that ovarian estrogen, potentially acting in conjunction with autocrine/paracrine factors such as hypoxia, has an essential physiologic role in stimulating VEGF expression by endometrial glandular epithelial and stromal cells (Fig. 1), thereby promoting angiogenesis and the progressive development of a new vascular system necessary to support growth and differentiation of the endometrium during the menstrual cycle.

It is also apparent that studies to this point have focused primarily on VEGF expression in the uterus. Thus, very little is known about the regulation of other angiostimulatory components, e.g. angiopoietin-1 and -2, required for vessel maturation and development. Moreover, although cell culture studies show that angiogenesis involves a balance between stimulatory and inhibitory factors, very little is known about the timing of expression and regulation of angioinhibitory factors such as thrombospondin, and how they interact with angiostimulators, such as VEG/PF and angiopoietin-1 and -2, in promoting vessel development in the human and nonhuman primate endometrium.

## Angiogenesis in the Primate Endometrium

Experimental evidence also shows that development and remodeling of the vascular bed in the endometrium involves complex cell-cell and cell-extracellular matrix interactions, including the mural investment of vascular endothelial cells with pericytes and vascular smooth muscle cells. However, very little is known about the particular roles which estrogen and progesterone, acting directly or indirectly via VEGF, angiopoietins-1/-2, and other stimulatory and inhibitory growth factors, play in the latter architectural processes. Moreover, the actions which estrogen and progesterone have in regulating cell adhesion molecules, integrins, and proteinases integral to these cellular remodeling processes for endometrial angiogenesis during the menstrual cycle are largely unknown.

Finally, the uterine endometrium is a heterogeneous organ comprised of vascular components, secretory glandular and luminal epithelial cells, and stromal elements including immunomodulatory macrophages and fibroblasts, each of which may display a very different repertoire of steroid hormone responsiveness, expression of cell-cell matrix molecules, and autocrine/paracrine molecular interaction. Relatively little attention has been directed, however, to cell-specific responsiveness and function in the human endometrium with respect to the steroid hormone regulation of angiogenesis.

## 8. ACKNOWLEDGMENT

The work on endometrial angiogenesis conducted in the authors' laboratories and referenced in this review was supported by NIH U54 HD-36207 as part of the NICHD Specialized Cooperative Centers Program in Reproduction Research.

## 9. REFERENCES

1. F C Greiss Jr & J C Rose: Vascular physiology of the nonpregnant uterus. In: *Biology of the Uterus*. Eds: Wynn R. M., Jollie W. P., Plenum Medical Book Co., NY, 69-87 (1989)
2. E M Ramsey: Anatomy of the uterus. In: *The Uterus*. Eds: Chard T., Grudzinskas J. G., Cambridge University Press, Cambridge UK (1994)
3. Reynolds L P, S. D. Killilea & D. A. Redmer: Angiogenesis in the female reproductive system. *FASEB J* 6, 886-892 (1992)
4. Brenner R M & O. D. Slayden: Cyclic changes in the primate oviduct and endometrium. In: *The Physiology of Reproduction*. Eds: Knobil E, Neill J. D., Raven Press, Ltd., NY 541-569 (1994)
5. Ferrara N & T. Davis-Smyth: The biology of vascular endothelial growth factor. *Endocr Rev* 18, 4-25 (1997)
6. Hanahan D: Signal vascular morphogenesis and maintenance. *Science* 277, 48-50 (1997)
7. Maisonpierre P C, C. Suri, P. F. Jones, S. Bartunkova, S. J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T. H. Aldrich, N. Papadopoulos, T. J. Daly, S. Davis, T. N. Sato & G. D. Yancopoulos: Angiopoietin-2, a natural antagonist for Tie 2 disrupts *in vivo* angiogenesis. *Science* 277, 55-60 (1997)
8. Markee JE: Menstruation in intraocular endometrial transplants in the rhesus monkey. *Contrib Embryol* 177, 221-308 (1940)
9. Noyes R W, A. T. Hertig & J. Rock: Dating the endometrial biopsy. *Fertil Steril* 1, 3-25 (1950)
10. Klagsbrun M & P. A. D'Amore: Regulators of angiogenesis. *Ann Rev Physiol* 53, 217-239 (1991)
11. Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. *Rec Progr Horm Res* 55, 15-36 (2000)
12. Ferrara N, K. Houck, L. Jakeman & D. W. Leung: Molecular and biological properties of the vascular endothelial growth factor family of proteins. *Endocr Rev* 13:18-32 (1992)
13. Houck K A, N. Ferrara, J. Winer, G. Cachianes, B. Li & D. W. Leung: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol Endocrinol* 5, 1806-1814 (1991)
14. Leung D W, G. Cachianes, W. J. Kuang, D.V. Goeddel & N. Ferrara: Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science* 246, 1306-1309 (1989)
15. Gospodarowicz D, J. A. Abraham & J. Schilling: Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. *Proc Natl Acad Sci USA* 86, 7311-7315 (1989)
16. Houck K A, D. W. Leung, A. M. Rowland, J. Winer & N Ferrara: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. *J Biol Chem* 267, 26031-26037 (1992)
17. Cohen T, H. Gitay-Goren, R. Sharon, M. Shibuya, R. Halaban, B. Z. Levi & G. Neufeld: VEGF 121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding activity, requires cell surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. *J Biol Chem* 270, 11322-11326 (1995)
18. Kondo S, T. Matsumoto, Y. Yokoyama, I. Ohmori & H. Suzuki: The shortest isoform of human vascular endothelial growth factor permeability factor (VEGF/VPF 121) produced by *Saccharomyces cerevisiae* promotes both angiogenesis and vascular permeability. *Bba-Gen Subjects* 1243, 195-202 (1995)



## Angiogenesis in the Primate Endometrium

19. DeVries C, J. A. Escobedo, H. Ueno, K. Houck, N. Ferrara & L. T. Williams: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science* 255:989-991 (1992)
20. Shalaby F, J. Rossant, T. P. Yamaguchi, M. Gertsenstein, XF Wu, M. L. Breitman & A. C. Schuh: Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. *Nature* 376, 62-66 (1995)
21. Fong G H, J. Rossant, M. Gertsenstein & M. L. Breitman: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* 376, 66-70 (1995)
22. Kim K J, B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips & N. Ferrara: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth *in vivo*. *Nature* 362, 841-844 (1993)
23. Millauer B, L. K. Shawver, K. H. Plate, W. Risau & A. Ullrich: Glioblastoma growth inhibited *in vivo* by a dominant-negative flk-1 mutant. *Nature* 367, 576-579 (1994)
24. Fraser H M, S. E. Dickson, S. F. Lunn, C. Wulff, K. D. Morris, V. A. Carroll & R. Bicknell: Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. *Endocrinology* 141, 995-1000 (2000)
25. Ferrara N, H. Chen, T. Davis Smyth, H. P. Gerber, T. N. Nguyen, D. Peers, V. Chisholm, K. J. Hillan & R. H. Schwall : Vascular endothelial growth factor is essential for corpus luteum angiogenesis. *Nature Med* 4, 336-340 (1998)
26. Wulff C, H. Wilson, J. S. Rudge, S. J. Wiegand, S. F. Lunn & H. M. Fraser: Luteal angiogenesis: Prevention and intervention by treatment with vascular endothelial growth factor trap A40. *J Clin Endocrinol Metab* 86, 3377-3386 (2001)
27. Carmeliet P, V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, & K. Harpal: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 380, 435-439 (1996)
28. Ferrara N, K. Carver-Moore, H. Chen, M. Dowd, L. Lu, K. S. O'Shea, L. Powell-Braxton, K. J. Hillan & M. W. Moore: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* 380, 439-442 (1996)
29. Dumont D J, G. Gradwohl, G. H. Fong, M. C. Puri, M. Gertenstein, A. Auerbach & M. J. Breitman: Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. *Genes Dev* 8, 1897-1909 (1994)
30. Sato T N, Y. Tozawa, U. Deutsch, K. Wolburg-Buchholz, Y. Fujiwara, M. Gendron-Maguire, T. Gridley, H. Wolburg, W. Risau & Y. Qin: Distinct roles of the receptor kinases Tie-1 and Tie-2 in blood vessel formation. *Nature* 376, 70-74 (1995)
31. Akira S: Functional roles of STAT family proteins: lessons from knockout mice. *Stem Cells* 17, 138-146 (1999)
32. Loughna S & T. N. Sato: Angiopoietin and Tie signaling pathways in vascular development. *Matrix Biol* 20, 319-325 (2001)
33. Senger D R, S. R. Ledbetter, K. P. Claffey, A. Papadopoulos-Sergiou, C. A. Peruzzi & M. Detmar.: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alpha(v)beta3 integrin, osteopontin, and thrombin. *Am J Pathol* 149, 293-305 (1996)
34. Bikfalvi A, S. Klein, G. Pintucci & D. B. Rifkin: Biological roles of fibroblast growth factor-2. *Endocr Rev* 18, 26-45 (1997)
35. Wilkie A O M, G. M. Morris-Kay, E. Y. Jones & J. K. Heath: Functions of fibroblast growth factors and their receptors. *Curr Biol* 5, 500-507 (1995)
36. Montesano R, J. D. Vassalli, A. Baird, R. Guillemin & L. Orci: Basic fibroblast growth factor induces angiogenesis *in vitro*. *Proc Natl Acad Sci USA* 83, 7297-7301 (1986)
37. Gospodarowicz D, N. Ferrara, L. Schweigerer & G. Neufeld: Structural characterization and biological functions of fibroblast growth factor. *Endocr Rev* 8, 95-114 (1987)
38. Pepper M S, S. J. Mandriota, J. D. Vassalli, L. Orcil & R. Montesano: Angiogenesis-regulating cytokines: Activities and interactions. *Current Topics Microbiol and Immunol* 2, 31-67 (1996)
39. Klein S, M. Roghani & D. B. Rifkin: Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. *EXS* 79, 159-192 (1997)
40. Fox J C & J. R. Shanley: Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. *J Biol Chem* 271, 12578-12584 (1996)
41. Goto F, K. Goto, K. Weindel & J. Folkman: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. *Lab Invest* 69, 508-517 (1993)
42. Koolwijk P, K. Kapiteijn, B. Molenaar, E. VanSpronsen, B. VanDer Vecht, F. M. Helmerhorst & V. W. M. VanHinsberg: Enhanced angiogenic capacity and urokinase-type plasminogen activator expression by endothelial cells isolated from human endometrium. *J Clin Endocrin Metab* 86, 3359-3367 (2001)
43. Tille J C, J. Wood, S. J. Mandriota, S. Ferrari, J. Mestan, Z. Zhu, L. Witte & M. S. Pepper: Vascular

## Angiogenesis in the Primate Endometrium

- endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF-and basic fibroblast growth factor-induced angiogenesis *in vivo* and *in vitro*. *J Pharmacol Exper Therap* 299, 1073-1085 (2001)
44. Johnson D E & L. T. Williams: Structural and functional diversity in the FGF receptor multigene family. *Adv Cancer Res* 60, 1-41 (1993)
45. Cao Y, P. Linden, J. Farnebo, R. Cao, A. Eriksson, V. Kumar, J. H. Qi, L. Claesson-Welsh & K. Alitalo: Vascular endothelial growth factor C induces angiogenesis *in vivo*. *Proc Natl Acad Sci USA* 95, 14389-14394 (1998)
46. Cao Y, H. Chen, L. Zhou, M. K. Chiang, B. Anand-Apte, J. A. Weatherbee, Y. Wang, F. Fang, J. G. Flanagan & M. L. S. Tseng: Heterodimers of placenta growth factor/vascular endothelial growth factor. *J Biol Chem* 271, 3154-3162 (1996)
47. Fett J W, D. J. Strydom, R. R. Lobb, E. M. Alderman, J. L. Bethune, J. F. Riordan & B. L. Vallee: Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. *Biochemistry* 24, 5480-5486 (1985)
48. Nelson K G, T. Takahashi, N. L. Bossert, D. K. Walmer & J. A. McLachlan: Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. *Proc Natl Acad Sci USA* 88, 21-25 (1991)
49. Nguyen L L & P. A. D'Amore: Cellular interactions in vascular growth and differentiation. *Intl Rev Cytol* 204, 1-48 (2001)
50. Roberts A B, M. B. Sporn, R. K. Assoian, J. M. Smith, N. S. Roche, L. M. Wakefield, U. I. Heine, L. A. Liotta, V. Falanga, J. H. Kehrl & A. S. Fauci: Transforming growth factor type  $\beta$ : rapid induction of fibrosis and angiogenesis *in vivo* and stimulation of collagen formation *in vitro*. *Proc Natl Acad Sci USA* 83, 4167-4171 (1986)
51. Adams J C: Thrombospondin-1. *Int J Biochem Cell Biol* 29, 861-865 (1997)
52. IruelaArispe M L, P. Porter, P. Bornstein & E. H. Sage: Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. *J Clin Invest* 97, 403-412 (1996)
53. Nor J E, R. S. Mitra, M. M. Sutorik, D. J. Mooney, V. P. Castle & P. J. Polverini: Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. *J Vas Res* 37, 209-218 (2000)
54. Charnock-Jones D S, A. M. Sharkey, J. Rajput-Williams, D. Burch, J. P. Schofield, S. A. Fountain, C. A. Boocock & S. K. Smith: Identification and localization of alternatively spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. *Biol Reprod* 48, 1120-1128 (1993)
55. Torry D S, V. J. Holt, J. A. Keenan, G. Harris, M. R. Caudle & R. J. Torry: Vascular endothelial growth factor expression in cycling human endometrium. *Fert Steril* 66, 72-80 (1996)
56. Shifren J L, J. F. Tseng, C. J. Zaloudek, I. P. Ryan, Y. G. Meng, N. Ferrara, R. B. Jaffe & R. N. Taylor: Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. *J Clin Endocrinol Metab* 81, 3112-3118 (1996)
57. Ahmed A, C. Acevedo, S. Nijjar, J. D. Aplin, G. Yancopoulos & M. Sharns: Angiopoietin-1 and Tie-2 are down regulated in dysfunctional uterine bleeding. *J Soc Gynecol Invest* 7, (Suppl) Abst 52 (2000)
58. Krussel J S, E. M. Casan, F. Raga, J. Hirchenhain, Y. Wen, H. Y. Huang, P. Bielfeld & M. L. Polan: Expression of mRNA for vascular endothelial growth factor transmembranous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium. *Mol Hum Reprod* 5, 452-458 (1999)
59. Meduri G, P. Bausero & M. Perrot-Applanat: Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle. *Biol Reprod* 62, 439-447 (2000)
60. Möller B, C. Rasmussen, B. Lindblom & M. Olovsson: Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. *Mol Human Reprod* 7, 65-72 (2001)
61. Charnock-Jones D S, A. M. Macpherson, D. F. Archer, S. Leslie, W. K. Makkink, A.M. Sharkey & S. K. Smith: The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. *Human Reprod* 15, 85-95 (2000)
62. Sharkey A M, K. Day, A. McPherson, S. Malik, D. Licence, S. K. Smith & D. S. Charnock-Jones: Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. *J Clin Endocrinol Metab* 85, 402-409 (2000)
63. Li X, J. Gregory & A. Ashmed: Immunolocalization of vascular endothelial growth factor in human endometrium. *Growth Factors* 11, 277-282 (1994)
64. Lau T M, B. Affandi & P. A. W. Rogers: The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. *Mol Hum Reprod* 5, 57-63 (1998)
65. Gargett C E, F. L. Lederman, T. M. Lau, N. H. Taylor & P. A. W. Rogers: Lack of correlation between vascular endothelial growth factor production and endothelial cell proliferation in the human endometrium. *Human Reprod* 14, 2080-2088 (1999)

## Angiogenesis in the Primate Endometrium

66. Niklaus A L, J. S. Babischkin, G. W. Aberdeen, G. J. Pepe & E. D. Albrecht: Expression of vascular endothelial growth/permeability factor by endometrial glandular epithelial and stromal cells in baboons during the menstrual cycle and after ovariectomy. *Endocrinology* 143, 4007-4017 (2002)
67. Rogers P A W, C. L. Au & B. Affandi: Endometrial microvascular density during the normal menstrual cycle and following exposure to long term levonorgestrel. *Hum Reprod* 8, 1396-1404 (1993)
68. Maas J W M, P. G. Groothuis, G. A. J. Dunselman, A. F. P. M. de Goeij, H. A. J. Struyker Boudier & J. L. H. Evers: Endometrial angiogenesis throughout the human menstrual cycle. *Human Reprod* 16, 1557-1561 (2001)
69. Goodger A M & P. A. W. Rogers: Endometrial endothelial cell proliferation during the menstrual cycle. *Hum Reprod* 9, 399-405 (1994)
70. Hornung D, D. I. Lebovic, J. L. Shifren, J. L. Vigne & R. N. Taylor: Vectorial secretion of vascular endothelial growth factor by polarized human endometrial epithelial cells. *Fertil Steril* 69, 909-915 (1998)
71. Nomura M, S. Yamagishi, S. Harada, Y. Hayashi, T. Yamashima, Y. Yamashita & H. Yamamoto: Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. *J Biol Chem* 270, 28316-28324 (1995)
72. Redmer D A, V. Doraiswamy, B. J. Bortnem, K. Fisher, A. Jablonka-Shariff, A. T. Grazul-Bilska & L. P. Reynolds: Evidence for a role of capillary pericytes in vascular growth of the developing ovine corpus luteum. *Biol Reprod* 65, 879-889 (2001)
73. Abramovitch R, M. Neeman, R. Reich, I. Stein, E. Keshet, J. Abraham, A. Solomon & M. Marikovsky: Inter-cellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. *FEBS Lett* 425, 441-447 (1998)
74. Gargett C E & P. A. W. Rogers: Human endometrial angiogenesis. *Reproduction* 121, 181-186 (2001)
75. Ferriani R A, D. S. Charnock-Jones, A. Prentice, E. J. Thomas & S. K. Smith: Immunohistochemical localization of acidic and basic fibroblast growth factors in normal human endometrium and endometriosis and the detection of their mRNA by polymerase chain reaction. *Human Reprod* 8, 11-16 (1993)
76. Glatstein I Z, Y. M. Choi, R. Osathanondh & J. Yeh: Human fetal uterine cells: culture, characterization, and analysis of growth factor receptor gene expression. *J Clin Endocrinol Metab* 79, 126-133 (1994)
77. Sangha R K, X. F. Li, M. Shams & A. Ahmed: Fibroblast growth factor receptor-1 is a critical component for endometrial remodeling: localization and expression of basic fibroblast growth factor and FGF-R1 in human endometrium during the menstrual cycle and decreased FGF-R1 expression in menorrhagia. *Lab Invest* 77, 389-402 (1997)
78. Koga K, Y. Osuga, O. Tsutsumi, T. Yano, O. Yoshino, Y. Takai, H. Matsumi, H. Hiroi, K. Kugu, M. Momoeda, T. Fujiwara & Y. Taketani: Demonstration of angiogenin in human endometrium and its enhanced expression in endometrial tissues in the secretory phase and the decidua. *J Clin Endocrinol Metab* 86, 5609-5614 (2001)
79. Abberton K M, N. H. Taylor, D. L. Healy & P. A. Rogers: Vascular smooth muscle cell proliferation in arterioles of the human endometrium. *Hum Reprod* 14, 1072-1079 (1999)
80. Heath W F Jr, F. Moore, R. Bicknell & B. L. Vallee: Modulation of mitogenic stimuli by angiogenin correlates with *in vitro* phosphatidylinositol bisphosphate synthesis. *Proc Natl Acad Sci USA* 86, 2718-2722 (1989)
81. Garcia E, P. L. Bouchard, J. DeBrux, J. Berdah, R. Frydman, G. Schaison, E. Milgrom & M. Perrot-Appanat: Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating. *J Clin Endocrinol Metab* 67, 80-87 (1988)
82. Slayden O D & R. M. Brenner: RU486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (*Macaca mulatta*). *J Clin Endocrinol Metab* 78, 440-448 (1994)
83. Matsuzaki S, T. Fukaya, T. Suzuki, T. Murakami, H. Sasano & A. Yajimi: Oestrogen receptor  $\alpha$  and  $\beta$  mRNA expression in human endometrium throughout the menstrual cycle. *Mol Hum Reprod* 5, 559-564 (1999)
84. Critchley H O D, R. M. Brenner, T. A. Henderson, K. William, N. R. Nayak, Ov. D. Slayden, M. R. Millar & P. T. Saunders: Estrogen receptor  $\beta$ , but not estrogen receptor  $\alpha$ , is present in the vascular endothelium of the human and nonhuman primate endometrium. *J Clin Endocrinol Metab* 86, 1370-1378 (2001)
85. Okulicz W C, A. M. Savasta, L. M. Hoberg & C. Longcope: Biochemical and immunohistochemical analyses of estrogen and progesterone receptors in the rhesus monkey uterus during the proliferative and secretory phases of the artificial menstrual cycle. *Fertil Steril* 53, 913-920 (1990)
86. Okulicz W C, A. M. Savasta, L. M. Hoberg & C. Longcope: Immunofluorescent analysis of estrogen induction of progesterone receptor in the rhesus uterus. *Endocrinology* 125, 930-934 (1989)
87. Koji T & R. M. Brenner: Localization of estrogen receptor messenger ribonucleic acid in rhesus monkey uterus by nonradioactive *in situ* hybridization with digoxigenin-labeled oligodeoxynucleotides. *Endocrinology* 132, 382-392 (1993)

## Angiogenesis in the Primate Endometrium

88. Okulicz W C, M. Balsamo & J. Tast: Progesterone regulation of endometrial estrogen receptor and cell proliferation during the late proliferative and secretory phase in artificial menstrual cycles in the rhesus monkey. *Biol Reprod* 49, 24-32 (1993)
89. Snijders M., A. DeGoeij, M. J. C. Debets-Te Baerts, M. J. M. Rousch, J. Koudstaal & F. T. Bosman: Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. *J Reprod Fertil* 94, 363-371 (1992)
90. Okulicz W C, C. I. Ace & R. Scarrell: Zonal changes in proliferation in the rhesus endometrium during the late secretory phase and menses. *Proc Soc Exp Biol Med* 214, 132-138 (1997)
91. Padykula H A, L. G. Coles, J. A. McCracken, N. W. Jr King, C. Longcope & I. R. Kaiserman-Abramof: A zonal pattern of cell proliferation and differentiation in rhesus endometrium during the estrogen surge. *Biol Reprod* 31, 1103-1118 (1984)
92. Dvorak H F, L. F. Brown, M. Detmer & A. M. Dvorak: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* 146, 1029-1039 (1995)
93. Dvorak H F, J. A. Nagy, D. Feng, L. F. Brown & A. M. Dvorak: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. *Curr Topics Microbiol Immunol* 237, 917-132 (1999)
94. Clark J H & S. K. Mani: Actions of ovarian steroids. In: *The Physiology of Reproduction*. Eds: Knobil E, Neill J, Raven Press, NY 1011-1062 (1994)
95. Astwood E B: A six-hour assay for the quantitative determination of estrogen. *Endocrinology* 23, 25-31 (1938)
96. Stack G & J. Gorski: Direct mitogenic effect of estrogen on the prepubertal rat uterus: studies on isolated nuclei. *Endocrinology* 115, 1141-1150 (1984)
97. Friederici H H R: The early response of uterine capillaries to estrogen stimulation. *Lab Invest* 17, 322-333 (1967)
98. Cullinan-Bove K & R. D. Koos: Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. *Endocrinology* 133, 829-837 (1993)
99. Shweiki D, G. Neufeld, G. Itay-Goren & E. Kashet: Pattern of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. *J Clin Invest* 91, 2235-2243 (1993)
100. Hyder S M, G. M. Stancel, C. Chiappetta, L. Murthy, H. L. Boettger-Tong & S. Makela: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. *Cancer Res* 56, 3954-3960 (1996)
101. Hyder S M, J. C. Huang, Z. Nawaz, H. Boettger-Tong, S. Makela, C. Chiappetta & G. M. Stancel: Regulation of vascular endothelial growth factor expression by estrogens and progestins. *Environ Health Perspect* 108, 785-790 (2000)
102. Reynolds L P, J. D. Kirsch, K. C. Kraft & D. A. Redmer: Time-course of the uterine response to estradiol-17 $\beta$  in ovariectomized ewes: expression of angiogenic factors. *Biol Reprod* 59, 613-620 (1998)
103. Reynolds L P, J. D. Kirsch, K. C. Kraft, D. L. Knutson, W. J. McClafflin & D. A. Redmer: Time-course of the uterine response to estradiol-17 $\beta$  in ovariectomized ewes: Uterine growth and microvascular development. *Biol Reprod* 59, 606-612 (1998)
104. Hyder S M, C. Chiappetta & G. M. Stancel: Synthetic estrogen 17 $\alpha$ -ethinyl estradiol induces pattern of uterine gene expression similar to endogenous estrogen 17 $\beta$ -estradiol. *J Pharmacol Exp Ther* 290, 740-747 (1999)
105. Hyder S M, C. Chiappetta, L. Murthy & G. M. Stancel: Selective inhibition of estrogen-regulated gene expression *in vivo* by the pure antiestrogen ICI 182,780. *Cancer Res* 57, 2547-2549 (1997)
106. Johns A, A. D. Freay, W. Fraser, K. S. Korach & G. M. Rubanyi: Disruption of estrogen receptor gene prevents 17 $\beta$  estradiol-induced angiogenesis in transgenic mice. *Endocrinology* 137, 4511-4513 (1996)
107. Mueller M D, J. L. Vigne, A. Minchenko, D. I. Lebovic, D. C. Leitman & R. N. Taylor: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors  $\alpha$  and  $\beta$ . *Proc Natl Acad Sci (USA)* 97, 10972-10972 (2001)
108. Taylor R N, D. I. Lebovic, D. Hornung & M. D. Mueller: Endocrine and paracrine regulation of endometrial angiogenesis. *NY Acad Sci* 109-121 (2001)
109. Huang J C, D. Y. Liu & M. Y. Dawood: The expression of vascular endothelial growth factor isoforms in cultured human endometrial stromal cells and its regulation by 17 $\beta$ -estradiol. *Mol Human Reprod* 4, 603-607 (1998)
110. Johannisson E: Effects of oestradiol and progesterone on the synthesis of DNA and the antihemophilic factor VIII antigen in human endometrial endothelial cells *in vitro*: a pilot study. *Hum Reprod* 1, 207-212 (1986)
111. Albrecht E D & G. J. Pepe: Endocrinology of Pregnancy. In: *Non-Human Primates in Perinatal Research*. Eds: Brans Y. W., Kuehl T. J., John Wiley and Sons, NY 13-78 (1988)
112. Niklaus A L, G. W. Aberdeen, J. S. Babischkin, G. J. Pepe & E. D. Albrecht: Effect of estrogen and

## Angiogenesis in the Primate Endometrium

progesterone on vascular endothelial growth/permeability factor expression by glandular epithelial and stromal cells in the baboon endometrium. *Biol Reprod* (2002, submitted)

113. Nayak N R & R. M. Brenner: Vascular proliferation and vascular endothelial growth factor expression in the rhesus macaque endometrium. *J Clin Endocrinol Metab* 87, 1845-1855 (2002)

114. Albrecht E D, G. W. Aberdeen, A. L. Niklaus, J. S. Babischkin, D. L. Suresch & G. J. Pepe: Acute temporal regulation of vascular endothelial growth/permeability factor expression and microvascular permeability in the baboon endometrium by estrogen. *J Clin Endocrinol Metab* (2002, submitted)

115. Presta M: Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. *J Cell Physiol* 137, 593-597 (1988)

116. Hyder S M & G. M. Stancel: Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. *Mol Endocrinol* 13, 806-811 (1999)

117. Hyder S M, Z. Nawaz, C. Chiappetta & G. M. Stancel: Detection of classical and atypical estrogen response elements in the untranslated regions of the rat VEGF gene. *Cancer Res* 60, 3183-3190 (2000)

118. Slayden O D, W. B. Zelinski-Wooten, K. Chwalisz, R. L. Stouffer & R. M. Brenner: Chronic treatment of cycling rhesus monkeys with low doses of the anti-progestin ZK 137316: morphometric assessment of the uterus and oviduct. *Hum Reprod* 13, 269-277 (1998)

119. Goodger-Macpherson A M, P. A. W. Rogers & B. Affandi: Endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel. *Hum Reprod* 9, 1647-1651 (1994)

120. Kaiserman-Abramof I R & H. A. Padykula: Angiogenesis in the postovulatory primate endometrium: the coiled arteriolar system. *Anat Rec* 224, 479-489 (1989)

121. Greb R R, O. Heikinheimo, R. F. Williams, G. D. Hodgen & A. L. Goodman: Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands *in vivo*. *Hum Reprod* 12, 1280-1292 (1997)

122. Classen-Linker I., J. Alfer, C. A. Krusche, K. Chwalisz, W. Rath & H. M. Beire: Progestins, progesterone receptor modulators, and progesterone antagonists change VEGF release of endometrial cells in culture. *Steroids* 65, 763-771 (2000)

123. Hourihan H M, B. I. Sheppard & J. Bonnar: The morphological response of blood vessels of the endometrium to low dose oral norethisterone and levonorgestrel. *J Obstet Gynecol* 11, 47-54 (1991)

124. Song J Y, R. Markham, P. Russell, T. Wong, L. Young & I. S. Fraser: The effect of high dose medium and long-term progestogen exposure on endometrial vessels. *Human Reprod* 10, 797-800 (1995)

125. Hickey M & I. S. Fraser: The structure of endometrial microvessels. *Human Reprod* 15, 57-66 (2000)

126. Hickey M, D. Dewart & I. S. Fraser: Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. *Human Reprod* 13, 3190-3196 (1998)

127. Nayak N R, H. O. D. Critchley, O. D. Slayden, A. Memrad, K. Chwalisz, D. T. Baird & R. M. Brenner: Progesterone withdrawal up-regulates vascular endothelial growth factor receptor type 2 in the superficial zone stroma of the human and macaque endometrium: Potential relevance to menstruation. *J Clin Endocrinol Metab* 85, 3442-3452 (2000)

128. Ancelin M, H. Buteau-Lozano, G. Meduri, M. Osborne-Pellegrin, S. Sordello, J. Plouet & M. Perrot-Applanat: A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF<sub>189</sub> regulates angiogenesis and vascular permeability in human uterus. *Proc Natl Acad Sci USA* 99, 6023-6028 (2002)

129. Hourihan H M, B. L. Sheppard & J. Bonnar: A morphometric study of the effect of oral norethisterone or levonorgestrel on endometrial blood vessels. *Contraception* 34, 603-612 (1986)

130. Smith S K: Angiogenesis, vascular endothelial growth factor and the endometrium. *Hum Reprod Update* 4, 509-519 (1998)

131. Bausero P, M. H. Ben-Mahdi, J. P. Mazucatelli, C. Bloy & M. Perrot-Applanat: Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. *Am J Physiol* 279, H2033-H-2042 (2000)

132. Colburn P & V. Buonassisi: Estrogen-binding sites in endothelial cell cultures. *Science* 201, 817-819 (1978)

133. Mendelsohn M E & R. H. Karas: The protective effects of estrogen on the cardiovascular system. *N Engl J Med* 340, 1801-1811 (1999)

134. Baker V L, V. A. Chao, J. T. Murai, C. J. Zaloudek & R. N. Taylor: Human umbilical vessels and cultured umbilical vein endothelial and smooth muscle cells lack detectable protein and mRNA encoding estrogen receptor. *J Soc Gynecol Invest* 4, 316-324 (1997)

135. Jenson I, C. H. Rinaldo, B. L. Nordbo, O. M. Seternes & U Moens: Human umbilical vein endothelial cells lack expression of the estrogen receptor. *Endothelium* 6, 9-21 (1998)

## Angiogenesis in the Primate Endometrium

136. Morales D E, K. A. McGowan, D. S. Grant, S. Maheshwari, D. Bhartiya, M. C. Cid, H. K. Kleinman & H. W. Schnaper: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells *in vitro* and in a murine model. *Circulation* 91, 755-763 (1995)

137. Schnaper H W, K. A. McGowan, S. Kim-Schulze & M. C. Cid: Oestrogen and endothelial cell angiogenic activity. *Clin Exp Pharm Physiol* 23, 247-250 (1996)

138. Spyridopoulos I, A. B. Sullivan, M. Kearney, J. M. Isner & D. W. Losordo: Estrogen receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. *Circulation* 95, 1505-1514 (1997)

139. Gargett C E, M. Zaitseva, K. Bucak, S. Chu, P. J. Fuller & P. A. W. Rogers: 17 $\beta$ -Estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: role of estrogen receptor  $\alpha$  and  $\beta$ . *J Clin Endocrinol Metab* 87, 4341-4349 (2002)

140. Heryanto B & P. A. W. Rogers: Regulation of endometrial endothelial cell proliferation by oestrogen and progesterone in the ovariectomized mouse. *Reproduction* 123, 107-113 (2002)

141. Folkman J: Is tissue mass regulated by vascular endothelial cell? Prostate as the first evidence. *Endocrinology* 139, 441-442 (1998)

142. Bausero P, F. Cavaille, G. Meduri, S. Freitas & M. Perrot-Appalanat: Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. *Angiogenesis* 2, 167-182 (1998)

143. Concina P, S. Sordello, M. A. Barbacanne, R. Elhage, M. T. Pieraggi, G. Fournial, J. Plouet, F. Bayard & J. F. Arnal: The mitogenic effect of 17 $\beta$ -estradiol on *in vitro* endothelial cell proliferation and on *in vivo* reendothelialization are both dependent on vascular endothelial growth factor. *J. Vasc Res* 37, 202-208 (2000)

144. Popovici R M, J. C. Irvin, A. J. Giaccia & L. C. Giudice: Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: potential relevance to menstruation and endometrial regeneration. *J Clin Endocrinol Metab* 84, 2245-2248 (1999)

145. Lockwood C J, G. Krikun, A. B. C. Koo, S. Kadner & F. Schatz: Differential effects of thrombin and hypoxia on endometrial stromal and glandular epithelial cell vascular endothelial growth factor expression. *J Clin Endocrinol Metab* 87:4280-4286 (2002)

146. Tudor R M, B. E. Flook & N. F. Voelkel: Increased gene expression for VEGF and the VEGF receptors KDR/flk andflt in lungs exposed to acute or chronic hypoxia. *J Clin Invest* 95, 1798-1807 (1995)

147. Mandriotonet S J, P. A. Menoud & M. S. Pepper: Transforming growth factor  $\beta$ 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. *J Biol Chem* 271, 11500-11505 (1996)

**Key Words:** Endometrium, Angiogenesis, Steroids, Estrogen, Progesterone, Review

**Send correspondence to:** Dr. Eugene D. Albrecht, Department of Obstetrics, Gynecology and Reproductive Sciences, The Center for Studies in Reproduction, The University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201, Tel. 410-706-3391, Fax 410-706-5747, E-mail ealbrech@umaryland.edu

Initial studies on steroid hormone metabolism in the endometrium date back to 1965 with first demonstration of the STS activity, followed by investigation on the oxidative and reductive 17 $\beta$ HSD activities (Table 6 ). Both pre and postmenopausal tissues possess oxidative and reductive 17 $\beta$ HSD activities and the expression of 17 $\beta$ HSD1, 2, 4, 6, 7, 8, 10, 12, 14, and AKR1C3/17 $\beta$ HSD5 was detected at the mRNA or protein levels. Although the level of the single enzymes in the intracrine machinery varies with apparently no clear association with the disease condition, the intracrinological nature of endometriosis was recently proven by comparison between serum and tissue levels of steroids in 60 patients (eutopic and ectopic endometrium) and 16 controls. 1. Endometrial progesterone receptor (PR) expression. Steroid hormones are the systemic factors that drive the endometrium through the characteristic sequential phases of the menstrual cycle [12]. Steroids interact with their target cells via specific nuclear receptors with consequential initiation of gene transcription and a cascade of downstream molecular and cellular events. Smith SK: Regulation of angiogenesis in the endometrium. Trends Endocrinol Metab. 2001, 12: 147-51. The human endometrium develops new capillaries from existing microvessels, i.e. angiogenesis, which then undergo maturation and remodeling, i.e. investment of microvessels with periendothelial mural cells, into a new vascular network during each menstrual cycle. Improper vascularization of the endom Finally, further study is needed of cell-specific responsivity and function in the human endometrium with respect to steroid hormone regulation of angiogenesis.